Patient P-01605

Synthetic patientNBL-101 · Day 111 · 55–64 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient declined — Not now
Day 70 ME-01 recommended — Monitoring Escalation ME-01
Day 71 Patient accepted — Started ME-01 in the companion
Day 74 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days

Treatment adherence-9
Toxicity-3

What helped?

GI Support Protocol GI-04Day 57
Declined by patient
Monitoring Escalation ME-01Day 70
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
84% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 78 bpm
- Wearable964 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
- WearableSleep 4.8 h, below personal baseline
Inflammatory signalling ↓40
- BloodInflammatory load index 63
- WearableHRV 36 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 61

DNA

Fictional pharmacogenomic panel

CYP2D6 Intermediate metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.1 · butyrate capacity 31/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 35 ms
Sleep: 5.1 h
Steps: 1,192
Resting HR: 75 bpm

Daily log: GI score 60, nutritional resilience 34, adherence 40.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01582	60%	S14	GI-04	no change	45
P-01751	59%	S14	ME-01	improved	48
P-01564	57%	S14	ME-01	improved	39
P-01760	57%	S14	—	—	42
P-01732	56%	S14	ME-01	improved	45
P-01311	54%	S14	ME-01	improved	49
P-01728	54%	S14	SC-12	improved	41
P-01830	54%	S14	—	—	44
P-01463	53%	S14	NP-02	no change	41
P-01655	53%	S14	GI-04	no change	29
P-01619	52%	S14	GI-04	worsened	38
P-01735	52%	S14	—	—	40